Abbott Laboratories, US0028241000

Abbott Laboratories stock costs EUR 88.76 with target 20.8 percent higher

Published on 10/09/2026 at 19:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Barclays set a USD 120.00 target on October 7, 2026. Abbott Laboratories stock costs EUR 88.76 on October 9, 2026 versus EUR 88.04.

Key points in brief

  • Abbott Laboratories stock was EUR 88.76 at Lang & Schwarz on October 9, 2026, plus 0.82 percent versus EUR 88.04.
  • Barclays set a USD 120.00 target on October 7, 2026, 20.8 percent above the USD 99.30 NYSE price.
  • Abbott's USD 171.8 billion market capitalization and 31.9 P/E sit alongside a USD 81.97 to USD 134.50 52-week range.
  • Third-quarter results are scheduled for October 21, 2026, before the market opens.
Modernes Diagnostik-Labor Abbott Laboratories US0028241000
Abbott Laboratories US0028241000 zeigt modernes Diagnostik-Labor mit Wissenschaftlern in weißen Laborkitteln an Analysesystemen, Illustration mit AI erstellt.

Abbott Laboratories (ISIN US0028241000) was at EUR 88.76 at Lang & Schwarz on October 9, 2026 at 7:39 p.m. CEST, plus 0.82 percent versus the prior close of EUR 88.04. According to MarketBeat on October 7, Barclays initiated coverage with a USD 120.00 target, which is 20.8 percent above Abbott's USD 99.30 NYSE price on October 9.

Bid ask spread stays contained

The Lang & Schwarz bid was EUR 88.62 and the ask was EUR 88.90 at 7:39 p.m. CEST. The US listing showed 2,782,958 shares traded at 1:43 p.m. ET, compared with an average volume of 9,644,404 shares.

Stock remains below yearly high

Abbott's NYSE price stood at USD 99.30 on October 9, 2026, inside a USD 81.97 to USD 134.50 52-week range. The price was 26.2 percent below the range high, while the USD 171.8 billion market capitalization placed the company among the larger medical-device groups.

Valuation and target in view

The finance quote showed a trailing P/E ratio of 31.9 for Abbott on October 9, 2026. Barclays' USD 120.00 target compares with the USD 99.30 NYSE price used for the 20.8 percent distance, while the euro quote remains the relevant price for German investors in this report.

Comparison with peers

Abbott Laboratories: plus 0.82 percent, P/E 31.9, market capitalization USD 171.8 billion
Medtronic (NYSE, USD): plus 0.3 percent, P/E 21.7, market capitalization USD 112.7 billion
Boston Scientific (NYSE, USD): plus 0.6 percent, P/E 17.2, market capitalization USD 62.8 billion

Next results date is October 21

Abbott will announce its third-quarter 2026 results before the market opens on October 21, 2026, according to Trivano in a September 30 release. The timing places the next major company-specific figure after the current price snapshot.

Euro quote after the Xetra close

The Lang & Schwarz price of EUR 88.76 was 0.82 percent above its EUR 88.04 prior close on October 9, 2026 at 7:39 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.

Abbott Laboratories stock facts

  • Company: Abbott Laboratories
  • ISIN: US0028241000
  • Ticker: ABT
  • Primary exchange: NYSE
  • Price Lang & Schwarz (as of October 9, 2026, 7:39 p.m. CEST): EUR 88.76
  • Change versus prior close: plus 0.82 percent
  • Prior close Lang & Schwarz (October 8, 2026): EUR 88.04
  • Market capitalization: USD 171.8 billion (as of October 9, 2026)
  • 52-week range: USD 81.97-134.50 (as of October 9, 2026)
  • Sector / Industry: Healthcare / Medical Devices
  • Next earnings date: October 21, 2026

Market context: Market report S&P 500.

More news and analyses on Abbott Laboratories stock

Disclaimer...

en | US0028241000 | ABBOTT LABORATORIES | boerse | 70282586 | bgmi